Skip to contentC
CV Sciences, Inc.
C
CVSICV Sciences, Inc. Q3 2022 · 10-Q
Revenue$3.75M$3.75M−26.6% vs Q3 2021 Net Income-$1.03M-$1.03MN/M vs Q3 2021 EPS Diluted-$0.01-$0.01— vs Q3 2021 Gross Profit$1,562,000−33.8% Operating Income
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
CV Sciences, Inc. · CIK 1510964 · Engraved from SEC EDGAR
Operating Cash Flowderived-$547,000N/M Free Cash Flowderived-$547,000N/M Margins · derivedGross margin41.6%−4.5 pt vs Q3 2021
Operating margin-23.8%+34.6 pt vs Q3 2021
Net margin-27.5%−26.7 pt vs Q3 2021
ended Sep 30, 2022 · filed Nov 14, 2022 · 45 d after period end